![](https://endpts.com/wp-content/uploads/2020/10/News_briefing_FE.jpg)
Hepalys to develop Inventiva’s NASH treatment; Everest licenses Kezar’s autoimmune drug
Hepalys Pharma said Thursday it will develop and commercialize Inventiva’s nonalcoholic steatohepatitis (NASH) treatment in Japan and South Korea, paying …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.